Analysis of published economic evaluations of angiotensin receptor blockers

Hellenic Journal of Cardiology

Volumn 50, Issue 2, 2009, Pages 105-118

  Theodoratou, Dorina ^a   Maniadakis, Nikos ^b   Fragoulakis, Vasilis ^c   Stamouli, Eugenia ^d  

^a Health Economics   (Greece)

^b NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^c Social Insurance Institute   (Greece)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Angiotensin receptor blockers; Cost effectiveness; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; NIFEDIPINE; OLMESARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DIABETIC HYPERTENSION; ECONOMIC EVALUATION; ESSENTIAL HYPERTENSION; GREECE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIFE EXPECTANCY; LOW DRUG DOSE; MONOTHERAPY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; HYPERTENSION;

EID: 65949111517     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. WHO Statistics [Internet]. [cited 2009 January 15]. Available from http://www.who.int/healthinfo/statistics/
2. Stefanadis CI. The future of antihypertensive treatment: from myth to imminent reality. Hellenic J Cardiol. 2008; 49: 377-378.
3. Pavlopoulos H, Nihoyannopoulos P. The constellation of hypertensive heart disease. Hellenic J Cardiol. 2008; 49: 92-99.
4. Pipilis A, Kaliambakos S, Xenodochidis C, Tsakonas G, Sourlas N, Mallios K. Overestimation and underestimation of cardiovascular risk in clinical practice: usefulness of risk estimation charts. Hellenic J Cardiol. 2007; 48: 341-345.
5. Marques-Vidal P, Arveiler D, Amouyel P, Bingham A, Ferrières J. Sex differences in awareness and control of hypertension in France. J Hypertens. 1997; 15: 1205-1210. (Pubitemid 27453171)
6. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25: 305-313.
7. De Henauw S, De Bacquer D, Fonteyne W, Stam M, Kornitzer M, De Backer G. Trends in the prevalence, detection, treatment and control of arterial hypertension in the Belgian adult population. J Hypertens. 1998; 16: 277-284. (Pubitemid 28101755)
8. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA. 2003; 289: 2363-2369.
9. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004; 22: 11-19.
10. Skliros E, Sotiropoulos A, Vasibossis A, et al. Poor hypertension control in Greek patients with diabetes in rural areas. The VANK study in primary care. Rural Remote Health. 2007; 7: 583.
11. Angelopoulos PD, Milionis HJ, Moschonis G, Manios Y. Relations between obesity and hypertension: preliminary data from a cross-sectional study in primary schoolchildren: the children study. Eur J Clin Nutr. 2006; 60: 1226-1234.
12. Stergiou GS, Thomopoulou GC, Skeva II, Mountokalakis TD. Prevalence, awareness, treatment, and control of hypertension in Greece: the Didima study. Am J Hypertens. 1999; 12 (10 Pt 1): 959-965.
13. Skliros EA, Papaioannou I, Sotiropoulos A, Giannakaki G, Milingou M, Lionis C. A high level of awareness but a poor control of hypertension among elderly Greeks. The Nemea primary care study. J Hum Hypertens. 2002; 16: 285-287.
14. Panagiotakos DB, Pitsavos CH, Chrysohoou C, et al. Status and management of hypertension in Greece: role of the adoption of a Mediterranean diet: the Attica study. J Hypertens. 2003; 21: 1483-1489.
15. Sarafidis PA, Lasaridis A, Gousopoulos S, et al. Prevalence, awareness, treatment and control of hypertension in employees of factories of Northern Greece: the Naoussa study. J Hum Hypertens. 2004; 18: 623-629.
16. Psaltopoulou T, Orfanos P, Naska A, Lenas D, Trichopoulos D, Trichopoulou A. Prevalence, awareness, treatment and control of hypertension in a general population sample of 26,913 adults in the Greek EPIC study. Int J Epidemiol. 2004; 33: 1345-1352.
17. Efstratopoulos AD, Voyaki SM, Baltas AA, et al. Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the Hypertension Study in General Practice in Hellas (HYPERTENSHELL) national study. Am J Hypertens. 2006; 19: 53-56.
18. Pitsavos C, Milias GA, Panagiotakos DB, Xenaki D, Panagopoulos G, Stefanadis C. Prevalence of self-reported hypertension and its relation to dietary habits, in adults; a nutrition & health survey in Greece. BMC Public Health. 2006; 6: 206.
19. Saito I, Kobayashi M, Matsushita Y. Pharmacoeconomical evaluation of combination therapy for lifetime hypertension treatment in Japan. Nippon Ishikai Zasshi. 2005; 48: 574-585.
20. Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan and irbesartan, Pharmacoeconomics. 2003; 21: 61-74. (Pubitemid 36078493)
21. Richer A, Gondek, Ostrowski C. Mild to moderate uncomplicated hypertension: further analysis of a cost effectiveness study of five drugs, Managed Care Interface. 2001; 14: 61-69.
22. Fujikawa K, Hasebe N, Kikuchi K. Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension. The Nifedipine and Candesartan Combination (NICE-Combi) study. Hypertens Res. 2005; 28: 585-591.
23. Hasebe N, Kikuch K. Controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens. 2005; 23: 445-453.
24. Lewis EJ, Hunsicker LG, Clarke WR. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345: 851-860.
25. Coyle D, Rodby R, Economic evaluation of the use of irbesartan, amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. Can J Cardiol. 2004; 20: 71-79.
26. Palmer AJ, Annemans L, Roze S, Lamotte M. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrology Dialysis Transplantation. 2003; 18: 2059-2066.
27. Palmer AJ, Annemans L, Roze S, Lamotte M, An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK settings. J Hum Hypertens. 2004; 18: 733-738. (Pubitemid 39369194)
28. Palmer A, Annemans L, Roze S, Lamotte A. Cost-effectiveness of irbesartan in type II diabetic nephropathy with hypertension. A Spanish perspective. Nefrologia. 2004; 24: 231-238.
29. Palmer AJ, Annemans K, Roze S. Health economic consequences of irbesartan treatment of type 2 diabetes patients with hypertension and nephropathy in Germany. Deutsch Med Wochenschr. 2004; 129: 13-18.
30. Palmer AJ, Annemans L, Roze S, Lamotte M. Cost-effectiveness analysis of irbesartan in patients with type-II diabetes, hypertension and nephropathy: the Italian perspective. Pharmacoeconomics - Italian Research Articles. 2005; 7: 43-47. (Pubitemid 40347326)
31. Rodby RA, Chiou CF, Borenstein J, Sneguota N. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther. 2003; 25: 2103-2119.
32. Palmer AJ, Annemans L, Roze S, Lapuerta P. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. Kidney International. 2005; 67 (Suppl 93): S52-S54
33. Palmer AJ, Roze S, Valentine WJ, Ray JA. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland. Swiss Med Wkly. 2006; 136: 346-352.
34. Palmer AJ, Valentine WJ, Ray JA. Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis. Eur J Health Econ. 2007; 8: 161-168. (Pubitemid 46742893)
35. Parving HH, Lehnert H, Brochner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2002; 345: 910-912.
36. Coyle D, Rodby R, Soroka S, Levin A. Cost-effectiveness of irbesartan 300mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective, Clin Ther. 2007; 29: 1508-1523.
37. Palmer AJ, Annemans L, Roze S, Lamotte M. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan in patients with type 2 diabetes, hypertension and renal disease. Diabetic Care. 2004; 27: 1897-1903. (Pubitemid 38989229)
38. Palmer AJ, Valentine WJ, Tucker DMD, Ray JA. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Curr Med Res Opin. 2006; 22: 2095-2100.
39. Palmer AJ, Valentine WJ, Ray JA. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. Int J Clin Pract. 2007; 61: 1626-1633.
40. McInnes G, Burke TA, Carides GW. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study. J Hum Hypertens. 2006; 20: 51-58.
41. Johnson B, Carides GW, Burke TA. Cost-effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. J Hypertens. 2005; 23: 1425-14131.
42. Szucs TD, Burnier M, Erne P. Cost-effectiveness of losartan versus atenolol in treating hypertension: an analysis of the LIFE study from a Swiss perspective. Cardiovasc Drugs Ther. 2004; 18: 391-397.
43. Boersma C, Carides GW, Atthobari J, Voors AA, Postma MJ. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to the Netherlands. Clin Ther. 2007; 29: 963-971.
44. Dahlof B, Devereux RB, Kjedsen SE. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995-1003.
45. Johnson L, Gerth WC, Fastbom J. The potential economic consequences of cognitive improvement with losartan. Blood Press. 2002; 11: 46-52.
46. Tedesco MA, Ratti G, Mennella S, et al, Comparison of losartan, hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens. 1999; 12: 1130-1134.
47. Stafilas P, Sarafidis P, Lasaridis A. An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece. Am J Hypertens. 2005; 18: 1233-1240.
48. Anis AH, Sun H, Singh S, Woolcott J. Cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy A. Pharmacoeconomics. 2006; 24: 387-400.
49. Johnson L, Carides DW, Burke TA, Brabdt AS, Salonen T, Schon S. Cost-effective prevention of renal failure in type 2 diabetics using losartan. J Med Econ. 2005; 8: 131-138.
50. Souchet T, Zaleski ID, Hannedouche T, Rodier M. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes Metab. 2003; 29: 29-35.
51. Vora J, Carides G, Robinson P. Effects of losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: a retrospective cost-effectiveness analysis in the United Kingdom. Curr Ther Res Clin Exp. 2005; 66: 475-485.
52. Alexander CM, Lyle PA, Keane WF, Carides GW. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. Kidney Int. 2004; 66 (Suppl 92): S115-S117.
53. Gerth WC, Remuzzi G, Viberti G. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Kidney Int. 2002; 62 (Suppl 82): S68-S72.
54. Herman ZW, Shahinfar S, Carides GW, Dasbach EJ. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care. 2003; 26: 683-687.
55. Burgess ED, Carides GW, Gerth WC, Marentette MA. Losartan reduces the costs associated with nephropathy and endstage renal disease from Type 2 diabetes: economic evaluation of the RENAAL study from a Canadian perspective. Can J Cardiol. 2004; 20: 613-618.
56. Carides GW, Shahinfar S, Dasbach EJ. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. PharmacoEconomics. 2006; 24: 549-558.
57. Seng WK, Hwang SJ, Han DC, Teong CC. Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. Nephrology. 2005; 10: 520-524.
58. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001; 3: 289-291.
59. Brenner BM, Cooper ME, DeZeeuw, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-869.
60. Smith DG, Nguyen AB, Peak CN. Markov modelling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria. French Journal of Managed Care Pharmacy. 2004; 10: 26-32.
61. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartran in patients with type 2 diabetes mellitus: a blood pressure -independent effect. Circulation. 2002; 106: 672-678.
62. Anderson AN, Wessels F, Moodley I. AT1 receptor blockers - cost-effectiveness within the South African context. S Afr Med J. 2000; 90: 494-498.